

# Beicheng Sun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4213070/publications.pdf>

Version: 2024-02-01

60  
papers

3,755  
citations

172457

29  
h-index

133252

59  
g-index

60  
all docs

60  
docs citations

60  
times ranked

6795  
citing authors

#	ARTICLE	IF	CITATIONS
1	The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. <i>Nature Cancer</i> , 2022, 3, 203-218.	13.2	38
2	Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. <i>Advanced Science</i> , 2022, 9, e2105894.	11.2	13
3	IL-33/ST2 signaling in liver transplantation. <i>Cellular and Molecular Immunology</i> , 2021, 18, 761-763.	10.5	6
4	Modulation of IR as a therapeutic target to prevent NASH using NRF from <i>Diceratella elliptica</i> (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF- $\kappa$ B inhibitor. <i>Phytomedicine</i> , 2021, 80, 153388.	5.3	3
5	Dorsal approach with Glissonian approach for laparoscopic right anatomic liver resections. <i>BMC Gastroenterology</i> , 2021, 21, 138.	2.0	3
6	Conjugated secondary 12 $\alpha$ -hydroxylated bile acids promote liver fibrogenesis. <i>EBioMedicine</i> , 2021, 66, 103290.	6.1	47
7	The zinc finger protein Miz1 suppresses liver tumorigenesis by restricting hepatocyte-driven macrophage activation and inflammation. <i>Immunity</i> , 2021, 54, 1168-1185.e8.	14.3	40
8	IL-22 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1290, 81-88.	1.6	52
9	A New Risk Score Based on Eight Hepatocellular Carcinoma-Immune Gene Expression Can Predict the Prognosis of the Patients. <i>Frontiers in Oncology</i> , 2021, 11, 766072.	2.8	2
10	The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. <i>Journal of Hepatology</i> , 2020, 72, 167-182.	3.7	116
11	Long noncoding RNA GMAN promotes hepatocellular carcinoma progression by interacting with eIF4B. <i>Cancer Letters</i> , 2020, 473, 1-12.	7.2	31
12	ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation. <i>Journal of Hepatology</i> , 2020, 72, 976-989.	3.7	36
13	lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway. <i>Cancer Management and Research</i> , 2020, Volume 12, 5395-5408.	1.9	21
14	PTPROt aggravates inflammation by enhancing NF- $\kappa$ B activation in liver macrophages during nonalcoholic steatohepatitis. <i>Theranostics</i> , 2020, 10, 5290-5304.	10.0	22
15	ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7814-7828.	3.6	12
16	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 731-741.	3.7	193
17	Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study. <i>United European Gastroenterology Journal</i> , 2019, 7, 933-941.	3.8	13
18	Guanine nucleotide-binding protein G(i) $\pm$ 2 aggravates hepatic ischemia-reperfusion injury in mice by regulating MLK3 signaling. <i>FASEB Journal</i> , 2019, 33, 7049-7060.	0.5	10

#	ARTICLE	IF	CITATIONS
19	Laennec's approach for laparoscopic anatomic hepatectomy based on Laennec's capsule. <i>BMC Gastroenterology</i> , 2019, 19, 194.	2.0	12
20	Liver Transplantation Using Right Lobe Graft With Focal Nodular Hyperplasia: Report of 2 Cases. <i>Transplantation Proceedings</i> , 2019, 51, 3347-3350.	0.6	0
21	14-3-3 $\eta$ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. <i>Cell Death and Disease</i> , 2018, 9, 159.	6.3	96
22	CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma. <i>Hepatology</i> , 2018, 68, 1865-1878.	7.3	55
23	Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. <i>Cell Death and Disease</i> , 2018, 9, 478.	6.3	122
24	Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. <i>Cellular and Molecular Immunology</i> , 2018, 15, 388-398.	10.5	81
25	The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. <i>Nature Communications</i> , 2017, 8, 15129.	12.8	271
26	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1041-1051.	8.7	12
27	Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor. <i>Medicine (United States)</i> , 2017, 96, e7295.	1.0	5
28	Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. <i>Oncotarget</i> , 2017, 8, 60149-60158.	1.8	110
29	Down-Regulation of LncRNA DGCR5 Correlates with Poor Prognosis in Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 707-715.	1.6	84
30	S100A4 hypomethylation affects epithelial-mesenchymal transition partially induced by LMP2A in nasopharyngeal carcinoma. <i>Molecular Carcinogenesis</i> , 2016, 55, 1467-1476.	2.7	15
31	Obesity and Cancer: The Oil that Feeds the Flame. <i>Cell Metabolism</i> , 2016, 23, 48-62.	16.2	296
32	Inhibition of MTA1 by ER $\alpha$ contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 128.	8.6	34
33	PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. <i>Oncotarget</i> , 2015, 6, 9420-9433.	1.8	27
34	PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma. <i>Journal of Molecular Cell Biology</i> , 2015, 7, 338-350.	3.3	11
35	PTPRO-Associated Hepatic Stellate Cell Activation Plays a Critical Role in Liver Fibrosis. <i>Cellular Physiology and Biochemistry</i> , 2015, 35, 885-898.	1.6	28
36	Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1187-1195.	3.0	30

#	ARTICLE	IF	CITATIONS
37	Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database. <i>Oncotarget</i> , 2015, 6, 633-641.	1.8	38
38	Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 10267-10273.	1.8	19
39	Survival and Inflammation Promotion Effect of PTPRO in Fulminant Hepatitis Is Associated with NF- $\kappa$ B Activation. <i>Journal of Immunology</i> , 2014, 193, 5161-5170.	0.8	21
40	Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes the Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma via Metastatic Tumor Antigen 1 and Mechanistic Target of Rapamycin Signaling Induction. <i>Journal of Virology</i> , 2014, 88, 11872-11885.	3.4	48
41	The therapeutic value of targeting inflammation in gastrointestinal cancers. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 349-357.	8.7	28
42	PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF- $\kappa$ B. <i>Journal of Hepatology</i> , 2014, 60, 306-312.	3.7	30
43	Reply. <i>Hepatology</i> , 2014, 59, 1208-1208.	7.3	5
44	IL-22 is related to development of human colon cancer by activation of STAT3. <i>BMC Cancer</i> , 2013, 13, 59.	2.6	157
45	IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation. <i>Journal of Immunology</i> , 2013, 191, 1835-1844.	0.8	256
46	Inflammation and liver tumorigenesis. <i>Frontiers of Medicine</i> , 2013, 7, 242-254.	3.4	78
47	ROR $\gamma$ t+IL-17+ neutrophils play a critical role in hepatic ischemia-reperfusion injury. <i>Journal of Molecular Cell Biology</i> , 2013, 5, 143-146.	3.3	62
48	Successful adult-to-adult liver transplantation of an otherwise discarded partial liver allograft with a cavernous hemangioma: new strategy for expanding liver donor pool. <i>Transplant International</i> , 2013, 26, e79-e80.	1.6	10
49	Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. <i>Hepatology</i> , 2013, 57, 678-688.	7.3	74
50	TGF- $\beta$ 2 Signaling Is Often Attenuated during Hepatotumorigenesis, but Is Retained for the Malignancy of Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e63436.	2.5	24
51	Obesity, inflammation, and liver cancer. <i>Journal of Hepatology</i> , 2012, 56, 704-713.	3.7	428
52	Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. <i>Hepatology</i> , 2011, 54, 900-909.	7.3	260
53	miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males. <i>Clinical Cancer Research</i> , 2011, 17, 5593-5603.	7.0	72
54	High expression levels of IKK $\alpha$ and IKK $\beta$ are necessary for the malignant properties of liver cancer. <i>International Journal of Cancer</i> , 2010, 126, 1263-1274.	5.1	58

#	ARTICLE	IF	CITATIONS
55	Hydrodynamics-based transfection of plasmid encoding receptor activator for nuclear factor kappa B-Fc protects against hepatic ischemia/reperfusion injury in mice. <i>Liver Transplantation</i> , 2010, 16, 611-620.	2.4	15
56	The level of oncogene H-Ras correlates with tumorigenicity and malignancy. <i>Cell Cycle</i> , 2008, 7, 934-939.	2.6	5
57	Late onset of severe graft-versus-host disease following liver transplantation. <i>Transplant Immunology</i> , 2006, 16, 250-253.	1.2	20
58	Immortal ALT+ Human Cells Do Not Require Telomerase Reverse Transcriptase for Malignant Transformation. <i>Cancer Research</i> , 2005, 65, 6512-6515.	0.9	18
59	The Minimal Set of Genetic Alterations Required for Conversion of Primary Human Fibroblasts to Cancer Cells in the Subrenal Capsule Assay. <i>Neoplasia</i> , 2005, 7, 585-593.	5.3	42
60	Progressive Loss of Malignant Behavior in Telomerase-Negative Tumorigenic Adrenocortical Cells and Restoration of Tumorigenicity by Human Telomerase Reverse Transcriptase. <i>Cancer Research</i> , 2004, 64, 6144-6151.	0.9	40